08.16.24 -- Portals For Productive Communication

The FDA recently announced it would exempt small dispensers from requirements of the Drug Supply Chain Security Act (DSCSA) until Nov. 27, 2026. The industry has made tremendous progress so far with DSCSA, but this discretion will make compliance more challenging.

Experts discuss the best time to start thinking about patient centricity, the steps developers can take to achieve patient-centric drug design, and how formulation and dosage forms can make a difference.

A gap exists between three months and three years in FDA-approved long-acting contraceptives. A microsphere formulation enables sustained release over six to twelve-months.

Explore case studies in the development and manufacturing of APIs and HPAPIs as well as solutions designed to address challenges in bringing new medicines to patients.

Industry experts answer attendee questions from a recent webinar about three enabling technologies designed to improve drug solubility in organic solvents for spray drying.

Early identification of absorption risks is critical for rapid and efficient drug development. Our PBPK modeling is designed to de-risk your drug development program.

We offer manufacturing services of oral solids at a pilot scale and drug products for clinical trials. We also offer full-scale commercial manufacturing service till you are ready with your own manufacturing facility to avoid delay in the commercial launch.

Dive into each service Altasciences provides as it relates to drug development for small molecules, elucidating how they can support and guide teams at every step.